show dates: Nov 1-3, 2022
location: Frankfurt, Germany
booth: 80D81
Ashland’s team of solvers is looking forward to seeing you at CPHI Frankfurt 2022. At the show, you will have the opportunity to discover our newest excipients.
When you're ready to formulate, we're ready to work with you!
Ashland introduces:
klucel™ xtend hydroxypropyl cellulose (HPC) controlled release matrix former, designed to deliver unsurpassed process versatility and release profile efficiency. It is the latest addition to our Klucel™ product line and further expands our controlled-release portfolio. Ashland’s step change klucel™ xtend HPC, has been shown to match the release profile of hypromellose controlled-release formulations at half the polymer concentration.
And we are featuring recent additions to our portfolio of injectable excipients:
viatel™ bioresorbable polymers that control release over time. These polymers are the building blocks for developing long-acting injectable (LAI)depots, an established technology to help improving therapeutic efficacy and improve patient compliance.
vialose™ trehalose dihydrate is a premier performance sugar resistant to acid hydrolysis and enzymatic cleavage. It is used to protect and shield biologic APIs, recombinant proteins, and monoclonal antibodies (mAbs) from degradation and aggregation and to stabilize and protect valuable components during the lyophilization process.
aquarius™ film-coating systems are our line of fully formulated, easily dispersed and ready-to-use have a range of functions to meet your needs: aesthetic or functional coatings, white or colored, with or without TiO2.
We offer the broadest selection of ingredients to compose effective pharmaceutical excipients. Migrating towards high impact and high value, we are widening our portfolio of cellulose-based polymers (HPMC, HPC, CMC, HEC), growing our excipient portfolio for injectables/biologics, including the possibility for customization, and focusing on film coatings. Oral solid dosage and liquid dosage ingredients, controlled release functionality, coatings, disintegrants, binders, and now, injectables compose Ashland’s pharma portfolio, and it is the diamond at the center of Ashland.
Excipient engineering and design to improve processing of oral controlled release formulations on-demand session
September 28 – November 18
Click here to watch our session to discover how to improve processing of oral controlled release formulations.
featured products
Dr. Christian Mühlenfeld
head of life sciences R&D
Europe, Middle East, & Africa
view our recent video:
klucel™ xtend HPC: New hydrophilic matrix polymer addresses the limitations of traditional hypromellose polymers
Learn how Ashland’s step change hydroxypropyl cellulose, klucel™ xtend hpc, has been shown to match the release profile of widely used hypromellose controlled-release formulations at half the polymer concentration.
©, Ashland. All rights reserved.
